These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 22142374)

  • 1. Kinetic studies to investigate lipoprotein metabolism.
    Borén J; Taskinen MR; Adiels M
    J Intern Med; 2012 Feb; 271(2):166-73. PubMed ID: 22142374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in the investigation of lipoprotein metabolism using tracer methodology.
    Chan DC; Watts GF
    Clin Lab; 2006; 52(7-8):353-61. PubMed ID: 16955633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipoprotein transport in the metabolic syndrome: methodological aspects of stable isotope kinetic studies.
    Chan DC; Barrett PH; Watts GF
    Clin Sci (Lond); 2004 Sep; 107(3):221-32. PubMed ID: 15225121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetic Studies to Elucidate Impaired Metabolism of Triglyceride-rich Lipoproteins in Humans.
    Adiels M; Mardinoglu A; Taskinen MR; Borén J
    Front Physiol; 2015; 6():342. PubMed ID: 26635628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms for therapeutic correction of dyslipidaemia in insulin resistance and diabetes.
    Watts GF; Chan DC
    Atheroscler Suppl; 2010 Jun; 11(1):61-4. PubMed ID: 20452838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies.
    Chan DC; Watts GF
    Expert Opin Pharmacother; 2011 Jan; 12(1):13-30. PubMed ID: 20629587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome.
    Adiels M; Olofsson SO; Taskinen MR; Borén J
    Arterioscler Thromb Vasc Biol; 2008 Jul; 28(7):1225-36. PubMed ID: 18565848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of atorvastatin on apolipoprotein B100 containing lipoprotein metabolism in type-2 diabetes.
    Ouguerram K; Magot T; Zaïr Y; Marchini JS; Charbonnel B; Laouenan H; Krempf M
    J Pharmacol Exp Ther; 2003 Jul; 306(1):332-7. PubMed ID: 12684543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased lipolysis by secretory phospholipase A(2) group V of lipoproteins in diabetic dyslipidaemia.
    Pettersson C; Fogelstrand L; Rosengren B; Ståhlman S; Hurt-Camejo E; Fagerberg B; Wiklund O
    J Intern Med; 2008 Aug; 264(2):155-65. PubMed ID: 18298481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: a stable isotope kinetic study.
    Duvillard L; Pont F; Florentin E; Galland-Jos C; Gambert P; Vergès B
    Eur J Clin Invest; 2000 Aug; 30(8):685-94. PubMed ID: 10964160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Catabolism of lipoproteins and metabolic syndrome.
    Therond P
    Curr Opin Clin Nutr Metab Care; 2009 Jul; 12(4):366-71. PubMed ID: 19474714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetic dyslipidaemia.
    Adiels M; Olofsson SO; Taskinen MR; Borén J
    Curr Opin Lipidol; 2006 Jun; 17(3):238-46. PubMed ID: 16680028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of oral contraceptives on lipid metabolism.
    Krauss RM
    J Reprod Med; 1986 Jun; 31(6 Suppl):549-50. PubMed ID: 3723487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipoprotein transport in the metabolic syndrome: pathophysiological and interventional studies employing stable isotopy and modelling methods.
    Chan DC; Barrett PH; Watts GF
    Clin Sci (Lond); 2004 Sep; 107(3):233-49. PubMed ID: 15225143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological regulation of dyslipoproteinaemia in insulin resistant states.
    Chan DC; Watts GF
    Curr Vasc Pharmacol; 2008 Jan; 6(1):67-77. PubMed ID: 18220942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma markers of cholesterol homeostasis and apolipoprotein B-100 kinetics in the metabolic syndrome.
    Chan DC; Watts GF; Barrett PH; O'Neill FH; Thompson GR
    Obes Res; 2003 Apr; 11(4):591-6. PubMed ID: 12690090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic regulation of apoB100 metabolism in insulin resistance in vivo.
    Watts GF; Ooi EM; Chan DC
    Pharmacol Ther; 2009 Sep; 123(3):281-91. PubMed ID: 19490928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of weight loss on markers of triglyceride-rich lipoprotein metabolism in the metabolic syndrome.
    Chan DC; Watts GF; Ng TW; Yamashita S; Barrett PH
    Eur J Clin Invest; 2008 Oct; 38(10):743-51. PubMed ID: 18837799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA regulation of mitochondrial and ER stress signaling pathways: implications for lipoprotein metabolism in metabolic syndrome.
    Christian P; Su Q
    Am J Physiol Endocrinol Metab; 2014 Nov; 307(9):E729-37. PubMed ID: 25184990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear magnetic resonance-determined lipoprotein abnormalities in nonhuman primates with the metabolic syndrome and type 2 diabetes mellitus.
    Ding SY; Tigno XT; Hansen BC
    Metabolism; 2007 Jun; 56(6):838-46. PubMed ID: 17512318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.